A Phase 2 interventional study of Placebo + methotrexate (MTX) (Group 1) and Ustekinumab + MTX (Group 2) in Arthritis, Rheumatoid, sponsored by Janssen Research & Development, LLC. Completed at 51 sites in 11 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2016-05-12.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 113 studies testing methotrexate in Arthritis, Rheumatoid — 8 open to participants now, 10 under way, 2 of them phase 3. Methotrexate · Arthritis, Rheumatoid.
Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, this one is the 36th largest by enrollment, is one of 11 that started in 2012, is one of 10 in phase 2, and was the 64th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →8 of the 113 studies testing methotrexate in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Keio University · Sites in Japan
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–65
Konkuk University Medical Center · Sites in Korea, Republic of
Ages 19+
Medical University of Vienna · Sites in Austria
Ages 18–99
By country, each count listing its studies:
Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
113 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 12 · Phase 3 48 · Phase 4 38
First in 1998; this study’s year is marked. 11 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 274 is above the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 130 across the 113 interventional studies. Of the 93 that completed or were terminated, 58 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
84 of 113 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
90 studies in Arthritis, Rheumatoid by Johnson & Johnson: 1 open now, 1 under way, none of them phase 3. Of 86 finished, 31 (36%) have results posted.
Among the 90 studies in Arthritis, Rheumatoid by Johnson & Johnson, this one is the 23rd largest by enrollment of the 75 interventional ones that give a count, is one of 8 that started in 2012, is one of 16 in phase 2, and was the 66th registered.
Johnson & Johnson’s Arthritis, Rheumatoid studies by the year they started, since 1997.
3 of the studies testing methotrexate in Arthritis, Rheumatoid that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05353829Region VästerbottenMethotrexate in Patients with Early Rheumatoid Arthritis | 2026-12-31 |
| NCT06590090XBiotech, Inc.Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment | 2027-01-15 |
| NCT06649136Medical University of ViennaMethMax Trial: MAXimising the METHotrexate Therapy Potential in Patients With Active Rheumatoid Arthritis | 2027-06-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, from their registry updates:
Among Johnson & Johnson’s 90 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy of ustekinumab and CNTO 1959 in reducing the signs and symptoms of disease in patients with active rheumatoid arthritis (RA) despite concomitant methotrexate (MTX) therapy and to evaluate the safety of ustekinumab and CNTO 1959 in this population.
This is a randomized (patients assigned to treatment by chance), double-blind (study personnel and patients will not know what treatment is being assigned to patients), multicenter, placebo-controlled (a placebo is a treatment identical in appearance to the study agent, but containing no active ingredient), dose-ranging study. Approximately 250 patients will be randomly assigned to 1 of 5 treatment groups. The maximum length of study participation is 54 weeks, including a 6-week screening period. The end of the study will be the last follow-up visit of the last patient. Study visits and evaluations will occur, and patient safety will be monitored throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo + methotrexate (MTX) (Group 1)
Drug: Ustekinumab + MTX (Group 2)
Drug: Ustekinumab + MTX (Group 3)
Drug: CNTO 1959 + MTX (Group 4)
Drug: CNTO 1959 + MTX (Group 5)
Placebo: form = solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28) + MTX (pre-study dose)
Drug pages: Ustekinumab · Methotrexate
Ustekinumab: type = exact number, unit = mg, number = 90, form = solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28) + MTX (pre-study dose)
Drug pages: Ustekinumab · Methotrexate
Ustekinumab: type = exact number, unit = mg, number = 90, form = solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 12 weeks (Weeks 16 and 28) + MTX (pre-study dose)
Drug pages: Guselkumab · Methotrexate
CNTO 1959: type = exact number, unit = mg, number = 200, form = powder for solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28) + MTX (pre-study dose)
Drug pages: Guselkumab · Methotrexate
CNTO 1959: type = exact number, unit = mg, number = 50, form = powder for solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28)+ MTX (pre-study dose)
Percentage of Participants With American College of Rheumatology 20 (ACR 20) Response at Week 28
The ACR 20 responders are participants with at least 20 percent (%) improvement from Baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: 1) patient's assessment of arthritis pain-visual analog scale, 2) patient's global assessment of disease activity-visual analog scale, 3) physician's global assessment of disease activity-visual analog scale, 4) patient's assessment of physical function as measured by health assessment questionnaire-disability index (HAQ-Di), 5) C-reactive protein (CRP).
Time frame: Week 28
Change From Baseline in Disease Activity Index Score 28 (DAS28; Using C-reactive Protein [CRP]) Score at Week 28
The DAS28 calculated from the number of swollen joints (SJC) and painful joints (PJC) using the 28 joints count, CRP (mG/L) and patient's global assessment (PGA) of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 \<=3.2 = low disease activity, DAS28 \>3.2 to 5.1 = moderate to high disease activity.
Time frame: From Baseline to Week 28
Percentage of Participants With American College of Rheumatology 20 (ACR 20) Response at Week 12
The ACR 20 responders are participants with at least 20 percent (%) improvement from Baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: 1) Patient's Assessment of Arthritis Pain-Visual Analog Scale, 2) Patient's Global Assessment of Disease Activity-Visual Analog Scale, 3) Physician's Global Assessment of Disease Activity-Visual Analog Scale, 4) Patient's Assessment of Physical Function as measured by Health Assessment Questionnaire-Disability Index (HAQ-DI), 5) C-reactive Protein (CRP).
Time frame: Week 12
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Week 28
The Health Assessment Questionnaire-Disability Index (HAQ-DI): participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.
Time frame: Baseline and Week 28
| Milestone | Placebo | Ustekinumab 90 mg Every 8 Weeks | Ustekinumab 90 mg Every 12 Weeks | CNTO1959 200 mg Every 8 Weeks | CNTO1959 50 mg Every 8 Weeks |
|---|---|---|---|---|---|
| Started | 55 | 54 | 55 | 54 | 55 |
| Completed | 49 | 51 | 49 | 48 | 47 |
| Not completed | 6 | 3 | 6 | 6 | 8 |
| Withdrew: Death | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 4 | 0 | 2 | 4 | 5 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 2 | 1 |
| Withdrew: Other | 1 | 1 | 2 | 0 | 0 |
| Withdrew: Treatment not completed/completed f/u | 1 | 1 | 2 | 0 | 2 |
The ACR 20 responders are participants with at least 20 percent (%) improvement from Baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: 1) patient's assessment of arthritis pain-visual analog scale, 2) patient's global assessment of disease activity-visual analog scale, 3) physician's global assessment of disease activity-visual analog scale, 4) patient's assessment of physical function as measured by health assessment questionnaire-disability index (HAQ-Di), 5) C-reactive protein (CRP).
| percentage of participants | Placebo | Ustekinumab 90 mg Every 8 Weeks | Ustekinumab 90 mg Every 12 Weeks | CNTO1959 200 mg Every 8 Weeks | CNTO1959 50 mg Every 8 Weeks |
|---|---|---|---|---|---|
| Percentage of Participants With American College of Rheumatology 20 (ACR 20) Response at Week 28 | 40.0 | 52.7 | 54.5 | 44.4 | 38.2 |
The DAS28 calculated from the number of swollen joints (SJC) and painful joints (PJC) using the 28 joints count, CRP (mG/L) and patient's global assessment (PGA) of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 \<=3.2 = low disease activity, DAS28 \>3.2 to 5.1 = moderate to high disease activity.
| units on scale | Placebo | Ustekinumab 90 mg Every 8 Weeks | Ustekinumab 90 mg Every 12 Weeks | CNTO1959 200 mg Every 8 Weeks | CNTO1959 50 mg Every 8 Weeks |
|---|---|---|---|---|---|
| Change From Baseline in Disease Activity Index Score 28 (DAS28; Using C-reactive Protein [CRP]) Score at Week 28 | -0.94 ± 0.174 | -1.52 ± 0.185 | -1.49 ± 0.183 | -1.21 ± 0.170 | 6.07 ± 0.821 |
The ACR 20 responders are participants with at least 20 percent (%) improvement from Baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: 1) Patient's Assessment of Arthritis Pain-Visual Analog Scale, 2) Patient's Global Assessment of Disease Activity-Visual Analog Scale, 3) Physician's Global Assessment of Disease Activity-Visual Analog Scale, 4) Patient's Assessment of Physical Function as measured by Health Assessment Questionnaire-Disability Index (HAQ-DI), 5) C-reactive Protein (CRP).
| percentage of participants | Placebo | Ustekinumab 90 mg Every 8 Weeks | Ustekinumab 90 mg Every 12 Weeks | CNTO1959 200 mg Every 8 Weeks | CNTO1959 50 mg Every 8 Weeks |
|---|---|---|---|---|---|
| Percentage of Participants With American College of Rheumatology 20 (ACR 20) Response at Week 12 | 29.1 | 37.0 | 34.5 | 33.3 | 20.0 |
The Health Assessment Questionnaire-Disability Index (HAQ-DI): participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.
| units on scale | Placebo | Ustekinumab 90 mg Every 8 Weeks | Ustekinumab 90 mg Every 12 Weeks | CNTO1959 200 mg Every 8 Weeks | CNTO1959 50 mg Every 8 Weeks |
|---|---|---|---|---|---|
| Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Week 28 | -0.30 ± 0.074 | -0.48 ± 0.072 | -0.44 ± 0.071 | -0.41 ± 0.075 | -0.39 ± 0.076 |
Collected over Week 0 to 48. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 3/55 (5.5%) | 13/55 (23.6%) |
| Placebo (Early Escape) | — | 1/16 (6.3%) | 6/16 (37.5%) |
| Ustekinumab 90 mg Every 8 Weeks | — | 4/54 (7.4%) | 15/54 (27.8%) |
| Ustekinumab 90 mg Every 12 Weeks | — | 3/55 (5.5%) | 15/55 (27.3%) |
| CNTO1959 200 mg Every 8 Weeks | — | 3/54 (5.6%) | 18/54 (33.3%) |
| CNTO1959 50 mg Every 8 Weeks | — | 0/55 (0%) | 14/55 (25.5%) |
| Event | Placebo | Placebo (Early Escape) | Ustekinumab 90 mg Every 8 Weeks | Ustekinumab 90 mg Every 12 Weeks | CNTO1959 200 mg Every 8 Weeks | CNTO1959 50 mg Every 8 Weeks |
|---|---|---|---|---|---|---|
| Rheumatoid ArthritisMusculoskeletal and connective tissue disorders | 1/55 | 1/16 | 0/54 | 0/55 | 0/54 | 0/55 |
| Lobar PneumoniaInfections and infestations | 0/55 | 0/16 | 0/54 | 0/55 | 1/54 | 0/55 |
| Urinary Tract InfectionInfections and infestations | 0/55 | 0/16 | 1/54 | 0/55 | 0/54 | 0/55 |
| ConcussionInjury, poisoning and procedural complications | 0/55 | 0/16 | 1/54 | 0/55 | 0/54 | 0/55 |
| SciaticaNervous system disorders | 0/55 | 0/16 | 1/54 | 0/55 | 0/54 | 0/55 |
| ShockVascular disorders | 0/55 | 0/16 | 1/54 | 0/55 | 0/54 | 0/55 |
| AnaemiaBlood and lymphatic system disorders | 0/55 | 0/16 | 1/54 | 0/55 | 0/54 | 0/55 |
| GastroenteritisInfections and infestations | 0/55 | 0/16 | 0/54 | 0/55 | 1/54 | 0/55 |
| Breast Cancer Stage INeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/55 | 0/16 | 0/54 | 0/55 | 1/54 | 0/55 |
| Angina UnstableCardiac disorders | 1/55 | 0/16 | 0/54 | 0/55 | 0/54 | 0/55 |
| Event | Placebo | Placebo (Early Escape) | Ustekinumab 90 mg Every 8 Weeks | Ustekinumab 90 mg Every 12 Weeks | CNTO1959 200 mg Every 8 Weeks | CNTO1959 50 mg Every 8 Weeks |
|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 3/55 | 1/16 | 5/54 | 4/55 | 4/54 | 3/55 |
| Rheumatoid ArthritisMusculoskeletal and connective tissue disorders | 1/55 | 0/16 | 2/54 | 5/55 | 4/54 | 2/55 |
| HeadacheNervous system disorders | 3/55 | 1/16 | 2/54 | 5/55 | 3/54 | 2/55 |
| HypertensionVascular disorders | 3/55 | 1/16 | 4/54 | 2/55 | 1/54 | 1/55 |
| BronchitisInfections and infestations | 1/55 | 0/16 | 2/54 | 2/55 | 4/54 | 2/55 |
| DyspepsiaGastrointestinal disorders | 1/55 | 1/16 | 0/54 | 0/55 | 0/54 | 0/55 |
| AstheniaGeneral disorders | 0/55 | 1/16 | 2/54 | 1/55 | 1/54 | 1/55 |
| PharyngitisInfections and infestations | 0/55 | 1/16 | 0/54 | 1/55 | 0/54 | 1/55 |
| Urinary Tract InfectionInfections and infestations | 0/55 | 1/16 | 0/54 | 1/55 | 0/54 | 0/55 |
| Aspartate Aminotransferase IncreasedInvestigations | 1/55 | 1/16 | 0/54 | 1/55 | 0/54 | 1/55 |
Analysis population included all randomized participants.
| Age, Continuous(years) | Placebo | Ustekinumab 90 mg Every 8 Weeks | Ustekinumab 90 mg Every 12 Weeks | CNTO1959 200 mg Every 8 Weeks | CNTO1959 50 mg Every 8 Weeks | Total |
|---|---|---|---|---|---|---|
| Mean | 51.1 ± 10.57 | 50.8 ± 13.01 | 51.4 ± 13.59 | 54.6 ± 11.34 | 49.9 ± 12.85 | 51.5 ± 12.34 |
| Sex: Female, Male(Participants) | Placebo | Ustekinumab 90 mg Every 8 Weeks | Ustekinumab 90 mg Every 12 Weeks | CNTO1959 200 mg Every 8 Weeks | CNTO1959 50 mg Every 8 Weeks | Total |
|---|---|---|---|---|---|---|
| Female | 48 | 46 | 47 | 42 | 45 | 228 |
| Male | 7 | 9 | 8 | 12 | 10 | 46 |
| Region of Enrollment(participants) | Placebo | Ustekinumab 90 mg Every 8 Weeks | Ustekinumab 90 mg Every 12 Weeks | CNTO1959 200 mg Every 8 Weeks | CNTO1959 50 mg Every 8 Weeks | Total |
|---|---|---|---|---|---|---|
| Argentina | 1 | 5 | 6 | 5 | 6 | 23 |
| Bulgaria | 2 | 2 | 2 | 2 | 1 | 9 |
| CZ Rep | 0 | 0 | 1 | 0 | 0 | 1 |
| Chile | 1 | 1 | 1 | 1 | 2 | 6 |
| Colombia | 10 | 9 | 8 | 6 | 10 | 43 |
| Hungary | 6 | 5 | 2 | 4 | 3 | 20 |
| Poland | 5 | 8 | 6 | 7 | 9 | 35 |
| Russia | 20 | 15 | 18 | 19 | 14 | 86 |
| Singapore | 1 | 1 | 0 | 2 | 0 | 4 |
| USA | 0 | 0 | 1 | 0 | 0 | 1 |
| Ukraine | 9 | 9 | 10 | 8 | 10 | 46 |
The record gives a start of Aug 2012, a primary completion of Dec 2013 and a completion of May 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2014, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ustekinumab · Methotrexate · Guselkumab
Janssen Research & Development, LLC →